CVS Q1 2025 Earnings: Growth, Guidance & Surprises

CVS beats Wall Street’s Q1 earnings estimates with strong financials.

[{"selector":"#anim-74e1d6ae-69c1-4d0b-8427-e41582b12f4c","keyframes":{"opacity":[0,1]},"delay":1000,"duration":900,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-e114bc27-2cfe-42b0-9709-ca8506d7a7a0","keyframes":{"transform":["translate3d(0px, 245.06401%, 0)","translate3d(0px, 0px, 0)"]},"delay":1000,"duration":900,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

Revenue hit $94.6B above analyst predictions of $93.6B.

[{"selector":"#anim-4089505d-93ac-4683-b91a-cc741708257b","keyframes":{"opacity":[0,1]},"delay":1000,"duration":900,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-ff4533c3-bdcc-4edc-8da7-93144e61af45","keyframes":{"transform":["translate3d(0px, 365.48729%, 0)","translate3d(0px, 0px, 0)"]},"delay":1000,"duration":900,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

CEO David Joyner credits success to strategy and execution

[{"selector":"#anim-b1d88730-b95c-462e-a117-fff1f13356ee","keyframes":{"opacity":[0,1]},"delay":1000,"duration":900,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-362d99d7-aa00-405f-8e67-54432bb67ede","keyframes":{"transform":["translate3d(0px, 168.83923%, 0)","translate3d(0px, 0px, 0)"]},"delay":1000,"duration":900,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

Medical loss ratio improved to 87.3%, down from 90.4%.

[{"selector":"#anim-18ae1e05-f2ca-4f18-ab5d-73508e9213fb","keyframes":{"opacity":[0,1]},"delay":1000,"duration":900,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-0b61afe4-59f2-4233-898a-f4362486f8c4","keyframes":{"transform":["translate3d(0px, 223.47531%, 0)","translate3d(0px, 0px, 0)"]},"delay":1000,"duration":900,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

Wegovy added to formulary as preferred weight-loss drug under Caremark.

[{"selector":"#anim-d9af50ff-3c21-4eaa-9f53-366289cca6a7","keyframes":{"opacity":[0,1]},"delay":1000,"duration":900,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-662876e7-5338-4f5e-bc33-3d5cd4243513","keyframes":{"transform":["translate3d(0px, 132.38667%, 0)","translate3d(0px, 0px, 0)"]},"delay":1000,"duration":900,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

Omnicare lawsuit charges impacted GAAP EPS—CVS plans to appeal

[{"selector":"#anim-f87eb7c4-95b7-4096-89e9-dd298467bfa5","keyframes":{"opacity":[0,1]},"delay":1000,"duration":900,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-f4b49414-d7db-4df9-aa26-77d6e0afe033","keyframes":{"transform":["translate3d(0px, 156.54873%, 0)","translate3d(0px, 0px, 0)"]},"delay":1000,"duration":900,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

CVS exits ACA marketplace, focusing on profitable coverage areas.

[{"selector":"#anim-24d661ee-3b17-41dd-8538-f18d3bb2dde2","keyframes":{"opacity":[0,1]},"delay":1000,"duration":900,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-1c576111-ea35-41dc-a408-6cde43255c06","keyframes":{"transform":["translate3d(0px, 135.97411%, 0)","translate3d(0px, 0px, 0)"]},"delay":1000,"duration":900,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

Full-year guidance raised: adjusted EPS now expected at $6.00–$6.20.

[{"selector":"#anim-fea36a38-cb1a-4185-8185-b518fef17e34","keyframes":{"opacity":[0,1]},"delay":1000,"duration":900,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-5fbc86a6-68e1-4d3a-83aa-4b3709a6cc07","keyframes":{"transform":["translate3d(0px, 342.02362%, 0)","translate3d(0px, 0px, 0)"]},"delay":1000,"duration":900,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] Learn more